Entropy CEO Jason Carroll said, “The DSMB’s recommendation to progress to Cohort 2 without any protocol changes is an important milestone for the TRP-8803 program and provides independent validation of the favourable safety profile observed in Cohort 1.” …
Entropy Neurodynamics clears safety hurdle for IV psilocin trial in binge eating disorder
June 15, 2026 Australian Biotech
Latest Video
New Stories
-
Entropy Neurodynamics clears safety hurdle for IV psilocin trial in binge eating disorder
June 15, 2026 - - Australian Biotech -
Paradigm reaches global milestone as Phase 3 osteoarthritis trial completes enrolment
June 15, 2026 - - Australian Biotech -
High Court to decide on patent‑term extensions for formulations as GBMA intervenes
June 15, 2026 - - Latest News -
Approach policy and pricing negotiations like planning for a product launch
June 15, 2026 - - Latest News -
The 'Dispatched' Week in Review'- 14 June
June 15, 2026 - - Podcast -
LifeSciences Australia honours outstanding professionals at MTP Sector Awards 2026
June 12, 2026 - - Latest News -
State and Territory ministers warn against centralising NDIS power
June 12, 2026 - - Latest News